Which Factors Predict Placebo Response in Anxiety Disorders and Major Depression? An Analysis of Placebo-Controlled Studies of Escitalopram
J Clin Psychiatry 2006;67(11):1741-1746
© Copyright 2016 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Background: The placebo response rate
has increased in several psychiatric disorders and is
a major issue in the design and interpretation of clinical trials. The current investigation
attempted to identify potential predictors of placebo
response through examination of the placebo-controlled clinical trial database for
escitalopram in 3 anxiety disorders and in major
depressive disorder (MDD).
Method: Raw data from
placebo-controlled studies (conducted from 2002 through the end
of 2004) of escitalopram in patients meeting DSM-IV criteria for MDD and anxiety disorders
(generalized anxiety disorder [GAD], social
anxiety disorder [SAD], panic disorder) were used.
Potential predictors examined were type of
disorder, location of study, dosing regimen, number
of treatment arms, gender of patients, and
duration and severity of disorder.
Results: Placebo response (defined as the
percent decrease from baseline in the reference scale) was higher in GAD and MDD studies
conducted in Europe (p < .0001 and p = .0006,
respectively) and was not associated with gender
or duration of episode. In GAD, the placebo response rate was higher in a European
fixed-dose study, which also had more treatment arms.
In SAD and in U.S. specialist-treated MDD, a higher placebo response rate was predicted
by decreased baseline disorder severity.
Conclusion: Additional work is needed
before definitive recommendations can be made
about whether standard exclusion criteria in
clinical trials of antidepressants, such as mild severity
of illness, maximize medication-to-placebo differences. This analysis in a range of anxiety
disorders and MDD suggests that there may be instances in which the predictors of
placebo response rate themselves vary across